HK-listed Hua Medicine hits 4-week high on progress of diabetes therapy

Hua Medicine

15/06/2020 05:33

** Shares of China's clinical-stage drug developer Hua
Medicine  2552.HK  rise as much as 19.5% to HK$5.34, their
highest level since May 19 
    ** The stock later trimmed gain to HK$5.08, still up 13.7%;
heading for biggest intraday pct gain since May 18
    ** Co, which focuses on developing novel therapies for the
treatment of diabetes, says its dorzagliatin product, a
glucokinase activator, exhibited positive impact on blood
glucose control with a good safety profile (https://bit.ly/2XYU1AO)
    ** Shanghai-based co says the post-analysis results
supporting its efforts of launching dorzagliatin as a
cornerstone therapy for the treatment of Type 2 Diabetes  
    ** As of last close, the stock has fallen 10.8% this year
    ** The Hang Seng China enterprises index  .HSCE  slides
0.5%, and the benchmark index  .HSI  falls 0.6%

 ((Reuters Messaging:
donny.kwok.thomsonreuters.com@reuters.net))